Last updated: Nov 19, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06600321 | 1 | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | BCAT mRNA -- RNA interference (siRNA) |
| NCT07884877 | 2 | PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer | Unknown mechanism |
| NCT05842174 | 1, 2 | Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma | Autophagy inhibition + chemotherapy -- hydroxychloroquine plus lipiodol |
| NCT05727787 | — | vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC | Unknown mechanism |
| NCT05003895 | 1 | GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies | GPC3 -- chimeric antigen receptor T cell therapy (CAR-T) |
| Sponsor | Recruiting trials |
|---|---|
| Sun Yat-sen University | 33 |
| Tianjin Medical University Cancer Institute and Hospital | 19 |
| Tongji Hospital | 15 |
| Second Affiliated Hospital of Guangzhou Medical University | 15 |
| Fudan University | 14 |
Countries/regions with the most active trial sites for hepatocellular carcinoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Dec 1, 2026 | NCT07878689 | Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma | Wnt pathway -- protein-protein interaction inhibitor (small molecule) |
| Nov 2026 | NCT07861425 | Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs | Glypican-3 (GPC-3) -- dual-payload antibody-drug conjugate (ADC) |
| Nov 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | STAT3 -- targeted protein degradation (degrader) |
| Oct 28, 2026 | NCT07430202 | A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | DNAJB1-PRKACA fusion kinase -- peptide vaccine plus glutamine antagonist plus PD-1 and CTLA-4 immune checkpoint inhibitors |
| Oct 7, 2026 | NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | GLP-1 receptor -- receptor agonist (GLP-1 RA) |
| Oct 1, 2026 | NCT07835737 | Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma | PD-L1 + VEGF -- bispecific antibody (Atezolizumab and Bevacizumab); Folic Acid -- metabolic supplement |
| Sep 30, 2026 | NCT07761286 | Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | VEGF -- monoclonal antibody (Bevacizumab); PD-1 -- immune checkpoint inhibitor (Sintilimab); Unknown target -- SYS6090 and SYS6043 mechanism unclear |
| Sep 1, 2026 | NCT07446257 | THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | PD-1 + CTLA-4 + nucleoside analog -- immune checkpoint inhibitor plus nucleoside analog |
You've seen the hepatocellular carcinoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.